Invented by Michael J Kelner, AF Chemicals LLC

The market for Affinity Medicant Conjugates (AMCs) is rapidly growing, with increasing demand from the pharmaceutical industry and potential for significant advancements in targeted drug delivery. AMCs are a class of therapeutics that combine the specificity of monoclonal antibodies (mAbs) with the potency of small molecule drugs, resulting in a highly effective and precise treatment option for various diseases. The concept of AMCs revolves around utilizing the binding capabilities of mAbs to selectively target specific cells or tissues in the body. By attaching a small molecule drug to the mAb, the drug can be delivered directly to the desired site, minimizing off-target effects and reducing systemic toxicity. This targeted approach has the potential to revolutionize the treatment of cancer, autoimmune diseases, and other conditions that require localized drug delivery. One of the key advantages of AMCs is their ability to enhance the therapeutic index of small molecule drugs. Small molecule drugs often have limited efficacy due to their non-specific distribution throughout the body, resulting in adverse effects and suboptimal therapeutic outcomes. By conjugating these drugs to mAbs, AMCs can specifically target cancer cells or disease-causing molecules, increasing drug concentration at the desired site and reducing exposure to healthy tissues. The market for AMCs is primarily driven by the increasing prevalence of cancer and the need for more effective treatment options. According to the World Health Organization (WHO), cancer is the second leading cause of death globally, with approximately 10 million deaths in 2020 alone. Conventional chemotherapy and radiation therapy, while effective to some extent, often come with severe side effects and limited efficacy. AMCs offer a promising alternative by specifically targeting cancer cells and delivering potent drugs directly to the tumor site, potentially improving patient outcomes and quality of life. In addition to cancer, AMCs also hold promise in the treatment of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and lupus. These conditions are characterized by an overactive immune system that mistakenly attacks healthy tissues. By conjugating immunosuppressive drugs to mAbs, AMCs can selectively target and suppress the immune cells responsible for the disease, reducing inflammation and preventing further damage. The market for AMCs is expected to witness significant growth in the coming years, driven by advancements in antibody engineering, drug discovery, and personalized medicine. The development of novel mAbs with improved binding affinity and specificity, as well as the identification of new small molecule drugs, will further expand the potential applications of AMCs. Additionally, the emergence of personalized medicine, which aims to tailor treatments based on individual patient characteristics, will likely drive the demand for targeted therapies like AMCs. However, there are challenges that need to be addressed for the widespread adoption of AMCs. The production of mAbs can be complex and expensive, requiring specialized manufacturing facilities and expertise. Furthermore, regulatory approval processes for novel therapeutics can be lengthy and rigorous, posing barriers to market entry. Overcoming these challenges will be crucial for the successful commercialization of AMCs and their integration into mainstream medical practice. In conclusion, the market for Affinity Medicant Conjugates is poised for significant growth, driven by the need for more effective and targeted treatment options in oncology and autoimmune diseases. AMCs have the potential to revolutionize drug delivery by combining the specificity of mAbs with the potency of small molecule drugs, resulting in improved therapeutic outcomes and reduced side effects. Continued advancements in antibody engineering, drug discovery, and personalized medicine will further propel the market and pave the way for the development of innovative and life-saving therapies.

The AF Chemicals LLC invention works as follows

In one embodiment, a composition used to treat a cell population contains an Affinity Medicant Combination (AMC). The medicant moiety may be a toxin containing an acylfulvene, or a drug. The affinity moiety may be an antigen, binding protein, growth factor, protein, non-peptidic, steroid, or lipid. The affinity moiety may be covalently attached to the medicant by a linker. Novel linkers can be directed at cysteine residues, arginine residues or lysine based on the pH of solution. This allows greater flexibility to preserve and/or generate specific epitopes within AMC.

Background for Affinity medicant conjugate

The present invention relates to Affinity Medicant Conjugates, including acylfulvene and Illudin based conjugates; Affinity Medicant Linker Conjugates, antibody-drug conjugates, and medicant-linker compounds (ML). It also relates to compositions containing the same and to their use for treating cancer and autoimmune diseases, and for methods to detect, diagnose, or treat cells and pathological conditions in vitro, on site, and in viv

There is a need to deliver chemotherapeutics that do not cause tumors to develop a resistant phenotype, which inhibit tumor growth and especially solid tumors, and have a therapeutic index sufficient for in-vivo treatment. The present invention’s antibody medicant conjugates can be used in a variety of therapeutic applications, both in humans and animals. These therapeutic applications include, for example: cancers such as adenocarcinoma and carcinomas, breast cancers, prostate cancers, ovarian tumors, endometrial tumours, neuroendocrine cancers, infertility (including polycysticovary syndrome), endometriosis and precocious pubescence. Veterinary and agricultural applications include, for example, treatment of cancers such as adenocarcinoma and carcinomas, ovarian and endometrial tumors, neuroendocrine tumours and endometriosis.

The methods of the invention include administering an effective amount, preferably as a pharmaceutical composition to an animal that is in need of it. In another embodiment, pharmaceutical compositions containing the antibody medicant conjugate are disclosed. The combination of an acceptable carrier and the antibody medicant is described.

In various embodiments, the affinity medicant conjugate consists of an antibody 1110 coupled to an illudin1 molecule 1301. The invention is directed at various embodiments for methods of preparation, use and pharmaceutical compositions that contain an illudin1 moieties 1301 coupled to an antigen 1110 in order to form an AMC. The AMC of various embodiments can have the formula shown in FIG. In 3A, the antibody is bound to linker 1200 that is bound to an illudin1 molecule 1301. The compounds of the AMC can also have the general formula in FIG. In 3B, a growth-factor 1120 is bound with a linker moiety 1200 that is bound with an illudin1 molecule 1301. “In various embodiments, the compounds of the invention include stereoisomers and solvates as well as pharmaceutically acceptable salts, wherein the linker 1200 as defined in table X and the illudin1 moiety 1301 as defined below in table XI.

In one embodiment, a species from the group consisting an antibody 1110, growth factor 1120, steroid 1 140, anti-angiogenic protein 1130, integrin-binding peptide peptide peptide peptide peptide peptide peptide peptide peptide peptide peptid peptide peptide peptide peptide peptide peptide peptide peptide peptide peptidie peptides 1150, glycopeptides 1150, glycopeptides, and,

In one embodiment of the invention, an illudin1 molecule 1301 is linked to a propeptide 1160 via a traditional linker. The enzyme then cleaves the linker and binds receptors for peptides. This directs the illudin1 molecule 1301 to cells expressing receptors.

In one embodiment, a species from the group consisting an antibody 1110 (growth factor), a glycopeptide or lipid, an anti-angiogenic protein 1130 (integrin binding) peptide, a cytokine, with a traditional linker (1240), to an illudin2 moieties 1302 binds a molecular to which an antibody, growth factor, steroid, anti-angiogenic protein, integrin-binding peptide, glycopeptide,

In one embodiment of the invention, an illudin2 molecule 1302 is linked to a propeptide 1160 via a traditional linker. This is then cleaved using an enzyme 1165. The illudin2 molecule 1302 then binds with receptors for the receptor and directs it to the cell populations that express the receptor.

The present invention includes a species that is selected from the group consisting an antibody 1110 (see FIG. The illudin1 molecule 1301 is bound to the molecule by the 1220.

The present invention is embodied in an illudin1 molecule 1301 that is linked to a FSB Linker via a FSB Linker. (See FIG. The enzyme 1165 cleaves the pro-peptide 1220 and then binds with receptors for the receptor and directs the Iludin1 moiety 13001 to the cell populations that express the receptor.

The present invention includes a species that is selected from a group of species consisting of an anti-angiogenic protein 1130, growth factor 1120 a, steroid 1140 a, glycopeptides 1170 and 1180 a, a linker FSB (see FIG. The illudin2 moieties 1302 are attached to the 15) 1220 and bind to the molecule that the antibody 1110 or growth factor 1120 or steroid is bound to.

In one embodiment of the invention, a FSB Linker 1220 is linked to a pro-peptide 1160 via illudin2 moieties 1302 (see FIG. The enzyme 1165 cleaves the pro-peptide 1220 and then binds the illudin2 molecule 1302 to the cell populations that express the receptor.

The present invention includes a selection of species from the group consisting an anti-angiogenic protein 1130, growth factor 1120 steroid 1140 glycopeptides 1170 and 1180 a linker FSB (see FIG. The binding of a protein toxins 1330 (1220) to a molecule that the antibody 1110 or growth factor 1120 or steroid is affixed to, and the peptides with biological activity, 1190, 1170, 1180, 1190, 1190, 1195, 1195, 1195, 1195, 1195, 1195, 1195, 1195, 1195, 1195, 1150, 1150, 1170, 1170, 1180, 1190, 1190

The present invention is a form of a protein toxin linked via a FSB Linker. (See FIG. The enzyme 1165 cleaves the pro-peptide 1220 and then binds with receptors for the receptor to direct the protein toxin to the cell population expressing the receptor.

The present invention includes a species that is selected from a group of species consisting of an anti-angiogenic protein 1130, a growth hormone 1120, an integrin binding polypeptide, 1150, glycopeptides 1170 and 1180, as well as a linker FSB (see FIG. The medicant 1220 binds a molecule that the anti-angiogenic protein 1130, growth factor 1120 steroid 1140, integrin binding peptide peptide peptide peptide peptide peptide peptide peptide peptide peptide peptidi 1150, glycopeptide peptide peptide peptide peptide peptide peptide peptide peptide peptide, lipid 1180 peptide with biologic

The present invention includes a medicant 1350 that is linked to a FSB Linker via a FSB Linker 1220 (see FIG. The enzyme 1165 cleaves the pro-peptide 1220 and then binds with receptors for peptides and directs medicant 1350 towards cell populations that express the receptor.

In one embodiment, a species from the group consisting an antibody 1110 (or growth factor), a hormone 1120 (or steroid), an anti-angiogenic protein 1130 (or integrin-binding peptide), a glycopeptide or lipid, 1170 and 1180 and 1195, with a linker Mal1 1210 attached to the illudin1 molecule 1301, binds a moiety to the molecule that the antibody, growth factor, hormone, or steroid, 1140, steroid,

In one embodiment of the invention, an illudin1 molecule 1301 that is linked to a propeptide 1160 via a Mal1 linker (1210) is cleaved using an enzyme 1165. The illudin1 molecule 1301 then binds with receptors for the receptor and directs it to the cell populations expressing receptors.

In one embodiment, a species from the group consisting an antibody 1110 (or a growth-factor 1120), an integrin-binding peptide (1150), a glycopeptide (170), a lipoprotein 1180 (or a mixture thereof), a biologically active peptide or a biologically active cytokine, with a linker Mal1 (1210) to an illudin2 1302 attaches to the molecule that the antibody, growth-factor,

In one embodiment of the invention, an illudin1 molecule 1301 linked to a propeptide 1160 via a Mal1 linker is cleaved using an enzyme 1165. The illudin2 molecule 1302 then binds with receptors for peptides and targets the cell populations that express the receptor.

In one embodiment, a species from the group consisting an antibody 1110 (growth factor), a glycopeptide (1130) and a mal1 linker (1210) to a protein toxins 1330 binds a specific molecule that the antibody 1110 (growth factor), the steroid 1140, the anti-angiogenic 1130 peptide, the Mal1 binding peptide, the glycopeptide (1130), the lipids (1180), the peptides with biological activities 1190 or 1195,

Click here to view the patent on Google Patents.